Zepto About Centricity Vision | Zepto

Committed to taking ophthalmology to greater heights

About Us

Our company name, Centricity Vision, Inc., reflects our company’s expertise, expanded product offerings in cataract surgery, and continued commitment to customers and patients.

As a global ophthalmic technology company, we take pride in delivering innovative solutions that help surgeons across the world achieve surgical and clinical excellence.

Currently, we’re focusing on our unprecedented ZEPTO IOL Positioning System™. Designed to enhance the precision and efficiency of cataract surgery, the ZEPTO IOL Positioning System™ is the first and only device that creates an instantaneous capsulotomy for precise, 360-degree IOL overlap and improved outcomes. ZEPTO is ideal for premium IOLs and complex cases that require enhanced precision. ZEPTO also provides significant cost and time savings with easy workflow integration and increased efficiency per case.

Moving forward, we’ll leverage this microsurgical technology to create a suite of products for refractive cataract surgery management. Our relentless commitment to developing solutions of the highest quality and technological sophistication is uncompromising—as is our dedication to assisting physicians in delivering the best care to patients.

See MoreSee Less

Leadership Team

Rob Thornhill

President & CEO

View Details
Louis Bunn

Chief Financial Officer

View Details
Todd M. Pinkney

Chief Commercial Officer

View Details
Dr. Leonard R. Borrmann

Head of Research and Development

View Details
Nealen Hartman

Vice President, RA and Quality Assurance

View Details
Rob Thornhill

President & CEO

View Details
Louis Bunn

Chief Financial Officer

View Details
Todd M. Pinkney

Chief Commercial Officer

View Details
Dr. Leonard R. Borrmann

Head of Research and Development

View Details
Nealen Hartman

Vice President, RA and Quality Assurance

View Details

News and Events

Upcoming News


New Study Shows Intraocular Lens Centration and Stability May Be Improved When ZEPTO Capsulotomy Platform is Used with Purkinje Reflections

Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the ZEPTO Platform to help achieve improved visual outcomes.

June 15, 2022
View Details

Centricity Vision Announces New Technologies Under Development, ZEPTOLINK and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&D

Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced two product innovations under development, the ZEPTOLINK platform and ZEPTO 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, Pharm. D, to lead research and development.

April 20, 2022
View Details

Centricity Vision CEO Rob Thornhill’s Exclusive Interview with The Ophthalmologist

Our CEO, Rob Thornhill, gave an exclusive interview to The Ophthalmologist before this year’s AAO meeting in New Orleans. See what Rob has to say about his vision for the company and his excitement at the difference being made by ZEPTO capsulotomy technology.

November 18, 2021
View Details

Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for ZEPTO Cataract Surgical Platform

Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, announced Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the ZEPTO Platform.

November 12, 2021
View Details

Introducing the Next Generation of ZEPTO®

Our next generation of ZEPTO® is here with over 16 newly enhanced features! Experience the new handpiece and new power console – now optimized with improved usability, enhanced safety and for strong capsulotomies with a 360° IOL overlap.

September 14, 2021
View Details

ZEPTO® Product Review – Ophthalmology Management July 2021 Issue

Centricity Vision is proud to be featured in the July edition of Ophthalmology Management with the next generation of ZEPTO® Spotlight Technology & Technique article. Click to open the PDF of the article.

July 20, 2021
View Details

Centricity Vision Appoints Jim Mazzo to its Board of Directors

Centricity Vision, Inc., a global ophthalmic technology company dedicated to delivering solutions that help surgeons achieve surgical and clinical excellence, today announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mazzo is one of the ophthalmic industry’s best known and most well respected business leaders with over 40 years of proven experience. “I am excited to join Centricity Vision’s Board of Directors and look forward to working with this exceptional team to increase global access to the ZEPTO Platform,” said Mazzo.

October 1, 2020
View Details

OIS Podcast: Listening to the Needs of the Customer from Centricity Vision’s Rob Thornhill

Dr. Ehsan Sadri and Rob Thornhill discuss the benefits of the Zepto Precision Cataract Surgery device in delivering automated, precise, circular, and centered capsulotomies – how their business model evolved during COVID-19 and the future direction for the company.

September 18, 2020
View Details

Mynosys Changes Name to Centricity Vision and Names New Leadership Team

Centricity Vision, Inc., formerly known as Mynosys Cellular Devices, Inc., a global ophthalmic technology company dedicated to delivering products that help surgeons optimize outcomes in refractive surgery, today announced a new executive leadership team, along with a new company name.

May 28, 2020
View Details

Upcoming Events


AAO 2022

Join Centricity Vision at the American Academy of Ophthalmology (AAO) in Chicago!

Chicago, IL
September 30 – October 3, 2022

September 19, 2022
View Details

REFERENCE 1: Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018;44(5):528-533.

Rob Thornhill

President & CEO

Rob is a start-up and large company medical device executive with equity fund-raising, business development, clinical study, and successful exit transactional experience. He has deep commercial operational experience with teams of up to 200 employees. Prior to joining Centricity Vision, Inc., Rob served as the founding CEO of Tear Film Innovations, Inc.,–manufacturer of the iLux treatment device for dry eye disease, which he led from seed stage through a Series B financing and then successfully sold to Alcon in 2018.

Close
Louis Bunn

Chief Financial Officer

Louis has more than 26 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising in excess of $200 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Prior to joining Centricity Vision, Louis was CFO of ReVision Optics, Inc., a corneal inlay company. Prior experience included serving as CFO and participating in the sale of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.

Close
Todd M. Pinkney

Chief Commercial Officer

Todd is a proven medical device and biotechnology commercial leader with an achievement record of more than 27 years. He demonstrated success in driving multimillion-dollar revenue growth while providing strategic marketing and sales leadership in highly competitive markets. Todd has commercial expertise in start-up, turnaround, and mature companies with significant business development and capital fundraising exposure. Prior to joining Centricity Vision, Todd led all commercial launch efforts for the XEN® Surgical Treatment System at Allergan. Todd graduated from Temple University with a Master’s Degree in International Business and holds a B.S. in Marketing from of Pittsburgh.

Close
Dr. Leonard R. Borrmann

Head of Research and Development

Dr. Leonard R. Borrmann brings a wealth of product development, clinical, and regulatory expertise to Centricity Vision leading R&D initiatives for the company. Dr. Borrmann joined Johnson & Johnson in 2017 with the acquisition of Abbott Medical Optics where he was the Divisional Vice President of Research and Development and retired from J&J as Global Head of External Innovation in 2020. Prior to joining Abbott, Dr. Borrmann held positions of increasing responsibility in R&D, including Executive Vice President R&D with Advanced Medical Optics (acquired by Abbott in 2009).  During his 13 years with AMO, Dr. Borrmann led the development and launch of more than 30 new products for AMO’s cataract, refractive and corneal businesses.  Prior to joining AMO, Dr. Borrmann was CEO and director for a series of venture-backed biotech companies and had a 15-year career at Allergan Pharmaceuticals Inc., where he held positions of increasing responsibility in Clinical Research, Marketing and Business Development, including Vice President of Business Development.

Dr. Borrmann earned his bachelor’s degree in Psychobiology and Doctor of Pharmacy degree from University of Southern California.

Close
Nealen Hartman

Vice President, RA and Quality Assurance

Nealen has more than 20 years of experience with start-ups to large medical device companies supporting regulatory affairs, quality assurance, and quality engineering. He gained FDA clearance and international registration of various types of devices ranging from single-use disposables to electro mechanical devices. Nealen established and maintained quality management systems that have been successfully audited and inspected by the FDA, notified bodies, and international entities. He was also involved with a handful of acquisitions, with the latest being the acquisition of Tear Film Innovation, Inc. by Alcon.

Close